Package Leaflet: Information for the User
SOMAVERT 10 mg powder and solvent for solution for injection
SOMAVERT 15 mg powder and solvent for solution for injection
SOMAVERT 20 mg powder and solvent for solution for injection
SOMAVERT 25mg powder and solvent for solution for injection
SOMAVERT 30mg powder and solvent for solution for injection
pegvisomant
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
Contents of the pack
SOMAVERT is used to treat acromegaly, a hormonal disorder resulting from increased secretion of growth hormone (GH) and IGF-I (insulin-like growth factor), and is characterized by overgrowth of bones, thickening of soft tissues, heart disease, and related disorders.
The active substance of SOMAVERT, pegvisomant, is known as a growth hormone receptor antagonist. These substances reduce the action of GH and IGF-I levels circulating in the blood.
Do not use SOMAVERT
Warnings and precautions
Talk to your doctor, pharmacist, or nurse before you start using SOMAVERT.
Other medicines and SOMAVERT
Tell your doctor if you have previously used another medicine for the treatment of acromegaly or any medicine for the treatment of diabetes.
Tell your doctor or pharmacist if you are using or have recently used any other medicines. As part of your treatment, you may be treated with other medicines. It is important that you continue to use all medicines, including SOMAVERT, unless your doctor, pharmacist, or nurse tells you otherwise.
Pregnancy, breastfeeding, and fertility
SOMAVERT is not recommended for use in pregnant women. If you are a woman of childbearing age, you should use a contraceptive method during treatment.
It is not known whether pegvisomant passes into breast milk. You should not breastfeed while taking SOMAVERT unless you have discussed it with your doctor.
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, ask your doctor or pharmacist for advice before using this medicine.
Driving and using machines
No studies have been performed on the effects on the ability to drive and use machines.
SOMAVERT contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per dose; this is essentially "sodium-free".
Follow exactly the administration instructions of this medicine given by your doctor or pharmacist. If you are unsure, ask your doctor or pharmacist again.
Your doctor will administer an initial dose of 80 mg of pegvisomant subcutaneously (under the skin). Then, the usual daily dose is 10 mg of pegvisomant administered by subcutaneous injection (under the skin).
Every 4-6 weeks, your doctor will make the necessary dose adjustments by increasing the dose by 5 mg of pegvisomant per day, according to your blood levels of IGF-I, in order to achieve an optimal therapeutic response.
Form and route of administration
SOMAVERT is injected under the skin. The injection can be given by you or another person, such as your doctor or helper. You should follow the detailed instructions on the injection process, which are included at the end of this leaflet. You should continue to inject this medicine for as long as your doctor tells you.
This medicine must be dissolved before use. The injection must not be mixed in the same syringe or vial with another medicine.
The fatty tissue under the skin may increase at the injection site. To avoid this, use slightly different injection points each time, as described in step 2 of the section of this leaflet "Instructions for preparation and administration of a SOMAVERT injection". This will give your skin and the area under the skin time to recover between injections before injecting again in the same place.
If you feel that the effect of this medicine is too strong or too weak, talk to your doctor, pharmacist, or nurse.
If you inject more SOMAVERT than you should
If you accidentally inject more SOMAVERT than your doctor told you, it is unlikely to be serious, but you should tell your doctor, pharmacist, or nurse immediately.
If you forget to use SOMAVERT
If you forget to give an injection, you should inject the next dose as soon as you remember and continue to inject SOMAVERT as prescribed by your doctor. Do not inject a double dose to make up for forgotten doses.
If you have any other questions about the use of this medicine, ask your doctor, pharmacist, or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Allergic reactions (anaphylactic) from mild to severe have been reported in some patients using SOMAVERT. Symptoms of a severe allergic reaction can include one or more of the following: swelling of the face, tongue, lips, or throat; wheezing or difficulty breathing (laryngeal spasm); widespread skin rash, hives, or itching; or dizziness. Contact your doctor immediately if you experience any of these symptoms.
Very common: may affect more than 1 in 10 people:
Common: may affect up to 1 in 10 people:
Uncommon: may affect up to 1 in 100 people:
Rare: cannot be estimated from the available data
About 17% of patients will develop antibodies to growth hormone during treatment. It seems that these antibodies do not affect the action of this medicine.
Reporting of side effects
If you experience any side effects, talk to your doctor, pharmacist, or nurse, even if they are not listed in this leaflet. You can also report side effects directly through the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the vials and on the carton after EXP. The expiry date is the last day of the month stated.
Store the vial(s) of powder in a refrigerator (between 2°C and 8°C) in its/their packaging to protect from light. Do not freeze.
The packaging(s) containing the vial(s) of SOMAVERT powder can be stored at room temperature up to a maximum of 25°C for a single period of up to 30 days. Write the expiry date on the packaging, including the day/month/year (up to 30 days from the date of removal from the refrigerator). The vial(s) must be protected from light. Do not put this medicine back in the refrigerator.
Discard this medicine if you do not use it before the new expiry date or the expiry date printed on the packaging, whichever is earlier.
Store the pre-filled syringe(s) at a temperature below 30°C or in a refrigerator (between 2°C and 8°C). Do not freeze.
After preparing the SOMAVERT solution, it must be used immediately.
Do not use this medicine if you notice that the solution is cloudy or contains particles.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
SOMAVERT Composition
Product Appearance and Container Contents
SOMAVERT is presented as a powder and solvent for injection (in a 10 mg, 15 mg, 20 mg, 25 mg, or 30 mg vial of pegvisomant and 1 ml of solvent in a pre-filled syringe). Package sizes of 1 and/or 30. Only some package sizes may be marketed.
The powder is white, and the solvent is transparent and colorless.
Marketing Authorization Holder and Manufacturer:
Marketing Authorization Holder
Pfizer Europe MA EEIG
Boulevard de la Plaine 17
1050 Bruxelles
Belgium
Manufacturer
Pfizer Manufacturing Belgium NV
Rijksweg 12
2870 Puurs-Sint-Amands
Belgium
You can request more information about this medicinal product by contacting the local representative of the marketing authorization holder:
België/Belgique/Belgien Luxembourg/Luxemburg Pfizer NV/SA Tel: +32 (0)2 554 62 11 | Lietuva Pfizer Luxembourg SARL filialas Lietuvoje Tel: +370 5 251 4000 |
Bulgaria Pfizer Bulgaria EOOD Tel: +359 2 970 4333 | Magyarország Pfizer Kft. Tel: +36 1 488 37 00 |
Ceská republika Pfizer, spol. s r.o. Tel: +420 283 004 111 | Malta Vivian Corporation Ltd. Tel: +356 21344610 |
Danmark Pfizer ApS Tlf: +45 44 20 11 00 | Nederland Pfizer bv Tel: +31 (0)800 63 34 636 |
Deutschland PFIZER PHARMA GmbH Tel: +49 (0)30 550055-51000 | Norge Pfizer AS Tlf: +47 67 52 61 00 |
Eesti Pfizer Luxembourg SARL Eesti filiaal Tel: +372 666 7500 | Österreich Pfizer Corporation Austria Ges.m.b.H. Tel: +43 (0)1 521 15-0 |
Ελλάδα Pfizer Ελλάς Α.Ε. Τηλ: +30 210 6785800 | Polska Pfizer Polska Sp. z o.o. Tel: +48 22 335 61 00 |
España Pfizer, S.L. Tel: +34 91 490 99 00 | Portugal Laboratórios Pfizer, Lda. Tel: +351 21 423 5500 |
France Pfizer Tél: +33 (0)1 58 07 34 40 | România Pfizer Romania S.R.L. Tel: +40 (0) 21 207 28 00 |
Hrvatska Pfizer Croatia d.o.o. Tel: +385 1 3908 777 | Slovenija Pfizer Luxembourg SARL Pfizer, podružnica za svetovanje s podrocja farmacevtske dejavnosti, Ljubljana Tel: +386 (0)1 52 11 400 |
Ireland Pfizer Healthcare Ireland Unlimited Company Tel: 1800 633 363 (toll free) Tel: +44 (0)1304 616161 | Slovenská republika Pfizer Luxembourg SARL, organizacná zložka Tel: +421 2 3355 5500 |
Ísland Icepharma hf. Sími: +354 540 8000 | Suomi/Finland Pfizer Oy Puh/Tel: +358 (0)9 430 040 |
Italia Pfizer S.r.l. Tel: +39 06 33 18 21 | Sverige Pfizer AB Tel: +46 (0)8 550 520 00 |
Κύπρος Pfizer Ελλάς Α.Ε. (Cyprus Branch) Τηλ: +357 22817690 | |
Latvija Pfizer Luxembourg SARL filiale Latvija Tel: +371 670 35 775 | |
Date of Last Revision of this Leaflet: 02/2025.
Other Sources of Information
Detailed information on this medicinal product is available on the European Medicines Agency website: https://www.ema.europa.eu. There are also links to other websites on rare diseases and orphan medicines.
INSTRUCTIONS FOR USE
SOMAVERT powder in vial with solvent in a pre-filled syringe
pegvisomant for injectable solution
For subcutaneous injection only
Single-dose vial
SOMAVERT is presented in a vial as a white powder block. You must mix SOMAVERT with a liquid (solvent) before you can use it.
The liquid is presented in a pre-filled syringe with the label "Solvent for SOMAVERT".
Do not mix SOMAVERT with any other liquid.
It is essential that you do not attempt to administer the injection to yourself or another person without having received training from your healthcare professional.
Store the carton containing the powder vial in the refrigerator between 2°C and 8°C and away from direct sunlight.
The packaging containing the powder vial of SOMAVERT can be stored at room temperature up to a maximum of 25°C for a single period of up to 30 days. Write the expiration date on the packaging, including the day/month/year (up to 30 days from the date of removal from the refrigerator). The vial must be protected from light. Do not put this medicine back in the refrigerator.
Discard this medicine if you do not use it before the new expiration date or the expiration date printed on the packaging, whichever comes first.
The pre-filled syringe of solvent can be stored at room temperature. Keep out of the reach of children.
A SOMAVERT package with:
You will also need:
Before starting:
Caution:Do not let anything touch the vial stopper.
Caution:Do not let the syringe tip touch anything once the cap is removed.
Caution:Do not let the needle touch anything.
Note:This may take up to 5 minutes.
Note:If you see air in the syringe, press the syringe cylinder to make the bubbles move up, and then slowly push the bubbles back into the vial.
Note:Make sure the needle is inserted all the way.
Note:You will hear a click when the needle protector closes.
QUESTIONS AND ANSWERS
What should I do if something accidentally touches the vial stopper?
What should I do with the syringe if it has fallen?
How many times can I safely insert the needle into the vial stopper?
Is it okay to shake the vial if the powder does not dissolve?
How can I tell if there is foam in the vial?
How can I avoid the medicine forming foam?
Can I see some air in the syringe? Is that okay?
Why can't I withdraw all the medicine from the vial?
What should I do if I have any doubts about the medicine?